← Back to Westminster Hall Debates

Medical Cannabis under Prescription: Children with Epilepsy

03 November 2021

Lead MP

Alberto Costa
South Leicestershire
Con

Responding Minister

Maria Caulfield

Tags

NHSTaxationLocal Government
Word Count: 8456
Other Contributors: 10

At a Glance

Alberto Costa raised concerns about medical cannabis under prescription: children with epilepsy in Westminster Hall. A government minister responded.

Key Requests to Government:

I urge the Government to consider covering the costs of private prescriptions for vulnerable children, using the discretionary fund available. I suggest conducting an observational trial or alternative study to enable free access to medical cannabis and improve evidence-based practice. Costa requests the Minister to utilise a discretionary fund to cover the costs of private prescriptions for children with epilepsy, providing a temporary solution until the regulatory process is completed.

How the Debate Unfolded

MPs spoke in turn to share their views and ask questions. Here's what each person said:

Lead Contributor

South Leicestershire
Opened the debate
I am concerned about the high costs families face for private prescriptions of medical cannabis, up to £2,000 a month. Only three prescriptions have been issued on the NHS since the law change in 2018. The guidance from various bodies has created confusion and hesitancy among prescribers. There is also concern that the expert panel set up by NICE does not include expertise on whole-plant extract medical cannabis. Alberto Costa is concerned about the impact of drug-resistant epilepsy on vulnerable children and highlights that many doctors are unwilling to prescribe medicinal cannabis due to its unlicensed status. He mentions specific cases such as Maya and Evelina who benefit from private prescriptions but cannot afford them.

Government Response

Maria Caulfield
Government Response
The Government recognises the strength of feeling on this issue and acknowledges that doctors are unwilling to prescribe medicinal cannabis due to its unlicensed status. The Minister explains that the Medicines and Healthcare Products Regulatory Agency (MHRA) requires a robust evidence base for licensing medicines, which includes research into adverse events and potential side effects. She notes that there are ongoing clinical trials, including randomised control trials, to gather this necessary data. The Government is committed to using every lever possible to speed up the research and licensing process to ensure doctors feel confident in prescribing medicinal cannabis.
Assessment & feedback
Summary accuracy

About Westminster Hall Debates

Westminster Hall debates are a chance for MPs to raise important issues affecting their constituents and get a response from a government minister. Unlike Prime Minister's Questions, these debates are more in-depth and collaborative. The MP who secured the debate speaks first, other MPs can contribute, and a minister responds with the government's position.